Thomas S. Uldrick, M.D.

Senior Clinician

HIV and AIDS Malignancy Branch


Building 10, Room 6N106
Bethesda, MD 20892


Research Topics

Dr. Uldrick's major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. Therapeutic studies focus on novel approaches to the treatment of several viral-associated malignancies using approaches that incorporate cytokine and growth factor manupulation and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antobodies or virus-activated cytotoxic therapy.

Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma, KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS) (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating, anti-angiogenic and virus-activated cytotoxic therapies (3) Evaluation of radiation-sparing approaches for HIV-associated primary CNS lymphoma, with an emphasis on long-term survival and neurocognitive functioning (4) Evaluation of human genomic alterations and gut associated lymphoid tissue in patients with anal cancer

Current collaborators include: Deborah Citrin, Radiation Oncology Branch, NCI Nancy Hessol, UCSF Frank Maldarelli, Drug Resistance Program, NCI Anisa Mosam, University of KwaZulu-Natal, South Africa Irini Sereti, Laboratory of Immunoregulation, NIAID Giovanna Tosato, Laboratory of Cellular Oncology, NCI Denise Whitby, Viral Oncology Section, NCI-Frederick HIV+ Tumor Molecular Characterization Project, Office of Cancer Genomics, NCI


Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.

Selected Publications

  1. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012;30(13):1476-83.

  2. Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-86.

  3. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350-8.

  4. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150-7.

  5. Uldrick TS, Pipkin S, Scheer S, Hessol NA. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS. 2014;28(3):397-405.

This page was last updated on June 15th, 2017